Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global ...
The summit convenes over 90 influential international healthcare officials, research and medical experts, start-ups, investors...
The NMPA acceptance of Chance Pharma’s first new drug application advances CXG87, an improved budesonide/formoterol dry powder inhalation therapy, toward potential commercialisation in China. ...
The platform’s creation is rooted in nearly a decade of deep collaboration by a cross-disciplinary team...
Both IV iron therapies are originator products already approved in China and included in the National Reimbursement Drug List (NRDL)...
Demonstrating a Favourable Safety Profile, Robust Immunogenicity, and Promising Preliminary Efficacy...
Delivery of three projects highlights growing adoption of AI-driven, scenario-based applications across enterprise and digital services...
CStone presents preclinical data on three differentiated antibody-drug conjugates, including a dual-target EGFR/HER3 candidate...
He played a key role in the development strategy for dapagliflozin, a leading SGLT-2 inhibitor that has become a global blockbuster in the treatment of metabolic diseases...
The strengthening of routine vaccine sales has contributed to a more balanced revenue mix and enhanced earnings visibility...
